Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03443999

S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System

Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System in a 'Real-World' Patient Population

Status
Recruiting
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
Sahajanand Medical Technologies Limited · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this registry is to evaluate the safety and efficacy of the Supraflex Family sirolimus-eluting coronary stent system in a 'real-world' patient population requiring stent implantation.

Detailed description

To overcome the potential drawback of the durable polymer a new generation of drug-eluting stent (DES) with a biodegradable polymer has been designed. The first-generation sirolimus-eluting or paclitaxel-eluting stents have a polymer release of antiproliferative drugs from a stainless steel stent platform. More recently, second generation DES have been developed not only to improve long-term DES safety but also to facilitate the procedure by using a cobalt-chromium (Co-Cr) stent platform. Co-Cr is stronger and more radiopaque than stainless steel, and thus allows strut thickness and total stent volume to be reduced while maintaining radial strength leading to a more flexible and deliverable stent platform. The Sahajanand Medical Technologies Pvt. Ltd. (SMT) has developed sirolimus-eluting stent that contain a biodegradable polymer coating and a Co-Cr stent platform. The purpose of this registry is to evaluate the Supraflex Family sirolimus-eluting stent in a 'real-world' patient population, in order to determine the safety and efficacy of the stent in wider usage.

Conditions

Interventions

TypeNameDescription
DEVICESupraflex Family Sirolimus-eluting Coronary Stent SystemPatient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care

Timeline

Start date
2018-02-27
Primary completion
2025-06-01
Completion
2025-12-01
First posted
2018-02-23
Last updated
2025-06-26

Locations

7 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT03443999. Inclusion in this directory is not an endorsement.